Endo International PLC (ENDPQ)

Endo Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. It operates through four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The Branded Pharmaceuticals segment offers products for the treatment of conditions in urology, orthopedics, and endocrinology. Its products include XIAFLEX, a non-surgical treatment for Peyronie’s Disease for adult men with a collagen plaque and a penile curvature deformity; and Dupuytren’s Contracture for adult patients with an abnormal buildup of collagen in the fingers that limits or disables hand function. This segment is also developing additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others are in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty. The Sterile Injectable segment offers ADRENALIN, a non-selective alpha- and beta-adrenergic agonist indicated for emergency treatment of certain allergic reactions, including anaphylaxis; and VASOSTRICT, a product indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. The Generic Pharmaceuticals segment provides solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, patches, powders, ophthalmics, and sprays, as well as products that treat and manage a rage of medical conditions. The International Pharmaceuticals segment sells a range of specialty pharmaceutical products primarily to customers in Canada. Its principal products serve various therapeutic areas, including attention deficit hyperactivity disorder, pain, women’s health, oncology, and transplantation, as well as over-the-counter products. The company was founded in 1997 and is headquartered in Malvern, Pennsylvania.